Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.

NHL Clinical Trial

Official title:

Anti-CD19 CAR NK Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma: a Multi-center, Uncontrolled Trial.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04639739
• Other study ID #: CAR NK for NHL
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: December 17, 2020
• Est. completion date: December 1, 2023

Study information

• Verified date: November 2020
• Source: Xinqiao Hospital of Chongqing
• Contact: Xi Zhang, MD phD
• Phone: 13808310064
• Email: zhangxxi[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are limitations of CAR-T cells, the consuming manufacturing time and expensive price exclude the majority of patients. therefore, we designed this trial to manifest the safety and efficacy of anti-CD19 CAR NK cell therapy in non-Hodgkin lymphoma

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 9
• Est. completion date: December 1, 2023
• Est. primary completion date: December 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Subjects must meet the following criteria for inclusion in the study: 1) Male or female subjects between the ages of 18 and 75(including critical values); 2) Subjects histologically confirmed as diffuse diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), primary mediastinal B cell lymphoma (PMBCL) and mantle cell lymphoma (MCL) :

1. Refractory B-NHL :Subjects of which the best response to standard first-line treatment is PD,(those intolerant to first-line treatment will not be included in this study). Subjects of which the best response to at least four courses of first-line treatment is SD, with a duration of SD less than 6 months after the last treatment. Subjects of which the best response to the last course of second-line treatment or above treatments is PD or the best response to at least two courses of second-line treatment or above treatments is SD, with a duration of SD less than 6 months.

2. Relapsed B-NHL:The disease relapses confirmed by histopathology in subjects who achieved complete remission after standard systematic treatment and second-line treatment. Or the disease relapses confirmed by histopathology within 1 year after hematopoietic stem cell transplantation (not limited to the previous therapeutic regimen) ; Male or female subjects between the ages of 18 and 75(including critical values); Subjects histologically confirmed as diffuse diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), primary mediastinal B cell lymphoma (PMBCL) and mantle cell lymphoma (MCL) :

Refractory B-NHL :Subjects of which the best response to standard first-line treatment is PD,(those intolerant to first-line treatment will not be included in this study). Subjects of which the best response to at least four courses of first-line treatment is SD, with a duration of SD less than 6 months after the last treatment. Subjects of which the best response to the last course of second-line treatment or above treatments is PD or the best response to at least two courses of second-line treatment or above treatments is SD, with a duration of SD less than 6 months.

Relapsed B-NHL:The disease relapses confirmed by histopathology in subjects who achieved complete remission after standard systematic treatment and second-line treatment. Or the disease relapses confirmed by histopathology within 1 year after hematopoietic stem cell transplantation (not limited to the previous therapeutic regimen) ;

Subjects with TFL must receive chemotherapy before transformation and meet the above definition of relapse or refractory after transformation.

According to Lugano response criteria 2014, there should be at least one evaluable tumor focus: the longest diameter of intranodal focus > 1.5cm, the longest diameter of extranodal focus > 1.0cm; Positive expression of CD19 in tumor tissue; Subjects who have no effect or relapse after single-target CAR-T treatment can also be included in the group.

Approved anti-tumor therapies, such as systemic chemotherapy, systemic radiotherapy, and immunotherapy, have been completed for at least 2 weeks before the precondition.

ECOG=1; Life expectancy = 3 months; Neutrophil absolute count = 1×10^9/L; platelet count = 50×10^9/L; Absolute lymphocyte count = 1×10^8/L ;

Adequate organ function reserve :

GPT, GST = 5× UNL(upper normal limit);

Serum total bilirubin =3× UNL; The left ventricular ejection fraction (LVEF) = 50% was diagnosed by echocardiography, and there was no clinically significant pericardial effusion and ECG abnormality; Basic oxygen saturation in indoor natural air environment > 92%; For female subjects of childbearing age, results are negative in urine pregnancy test before screening and administration, and subjects agree to take effective contraceptive measures at least one year after infusion; Male subjects with partners' fertility must agree to use effective barrier contraceptive methods at least one year after infusion, and avoid sperm donation; Voluntary signing of informed consent;

Exclusion Criteria:

Any of the following points shall be deemed as no entry into this study:

Other tumors except cured non-melanoma skin cancer, cervical cancer in situ, superficial bladder cancer, breast duct cancer in situ, or other malignant tumors with complete remission of more than 5 years);

Severe mental disorders;

A history of genetic diseases such as Fanconi anemia, Shudder-Dale syndrome, Costman syndrome, or any other known bone marrow failure syndrome;

History of allogeneic stem cell transplantation;

Heart disease with grade III-IV heart failure [NYHA classification], myocardial infarction, angioplasty or stenting, unstable angina or other heart diseases with prominent clinical symptoms within one year before admission;

Subjects with any indwelling catheter or drainage tube (such as percutaneous nephrostomy tube, bile drainage tube or pleura/peritoneum/pericardium catheter), should be excluded. (Special central venous catheter is allowed);

Subjects with a history of CNS lymphoma, CSF malignant cells, or brain metastasis;

Subjects with a history of CNS disease,such as epilepsy, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving CNS;

Any of the following virological ELISA results are positive: HIV antibody, HCV antibody, TPPA, HBsAg;

Active infection requiring systematic treatment within 2 weeks before single collection;

Subjects with known severe allergic reactions to cyclophosphamide or fludarabine, or diagnosed as the allergy;

History of autoimmune diseases (e.g. Crohn disease, rheumatoid arthritis, systemic lupus erythematosus) that cause end-organ damage or require systemic immunosuppressive medications or systemic disease modifying drugs in the past 2 years;

Presence of pulmonary fibrosis;

Subjects who have received other clinical trial treatment within 4 weeks before participating in this trial should be excluded. Or the signing date of informed consent is within 5 half-lives of the last application of another clinical trial (whichever is longer);

Subjects with poor compliance due to physiological, family, social, geographical and other factors, or those unable to cooperate with the study plan or follow-up; At the discretion of the investigator, there are complications requiring systemic corticosteroid therapy (= 5mg / day of prednisone or equivalent dose of other corticosteroids) or other immunosuppressive drugs within 6 months after this clinical research treatment;

The lactating woman who is reluctant to stop breastfeeding;

Any other condition considered unsuitable by the investigator.

Related Conditions & MeSH terms

• Lymphoma, Non-Hodgkin
• NHL

Intervention

Biological:
• anti-CD19 CAR NK
2×106 /kg?6×106 /kg?2×107/kg Treatment follows a lymphodepletion, the recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion,the actual regiment is determined by the statue of patients.

Locations

Country	Name	City	State
China	Department of Hematology, Xinqiao Hospital	ChongQing	Chongqing

Sponsors (2)

Lead Sponsor	Collaborator
Xinqiao Hospital of Chongqing	Chongqing Precision Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose limiting toxicity (DLTs)	To characterize the safety, tolerability, and determine the recommended dosage of Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma	within 4 weeks after infusion
Primary	Incidence and severity of AEs and SAEs	To characterize the safety, tolerability, and determine the recommended dosage of Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma	Up to 24 months
Secondary	The overall response rate(ORR)	to characterize the efficacy of Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma	1 and 3 months after infusion
Secondary	progression-free survival (PFS)	to characterize the efficacy of Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma	1, 3, 6, 12 and 24 months after infusion
Secondary	overall survival(OS)	to characterize the efficacy of Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma	1, 3, 6, 12 and 24 months after infusion